Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of potential inhibitor targeting KRAS mutation in Papillary Thyroid Carcinoma through molecular docking and dynamic simulation analysis.

Computers in biology and medicine - 1 Jan 2023

Tayubi Iftikhar Aslam, Madar Inamul Hasan

Abstract excerpt

Thyroid cancer is a predominant form of endocrine malignancy, which destabilizes the metabolic rate of the body. The rapid increase in the incidence rate of thyroid cancer in recent years has aroused great concern to be investigated and diagnosed at an early stage. This study aimed to analyze the pathogenic mutations in thyroid cancer to identify their potential inhibitors for therapeutic targets. RAS genes are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Papillary
Share to Molecular Docking Simulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Source

Identifiers

PMID: 36493736
DOI: 10.1016/j.compbiomed.2022.106377

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of potential inhibitor targeting KRAS mutation in Papillary Thyroid Carcinoma through molecular docking and dynamic simulation analysis.PMID 36493736Read ↗

Computational study of novel natural inhibitors targeting Kirsten rat sarcoma viral oncogene homolog G12C.Semantic proximity Read ↗

Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.Semantic proximity Read ↗

In silico profiling and structural insights of missense mutations in RET protein kinase domain by molecular dynamics and docking approach.Semantic proximity Read ↗

Targeting KRAS G12C and G12S mutations in lung cancer: In silico drug repurposing and antiproliferative assessment on A549 cellsSemantic proximity Read ↗

An updated literature on BRAF inhibitors (2018-2023).Semantic proximity Read ↗

CSC01 shows promise as a potential inhibitor of the oncogenic G13D mutant of KRAS: an in silico approach.Semantic proximity Read ↗

Bringing Structural Implications and Deep Learning-Based Drug Identification for KRAS Mutants.Semantic proximity Read ↗

G12V Kras mutations in cervical cancer under virtual microscope of molecular dynamics simulations.Semantic proximity Read ↗

Characterization of wild-type and mutated RET proto- oncogene associated with familial medullary thyroid cancer.Semantic proximity Read ↗

Identification of novel peptide inhibitors for oncogenic KRAS G12D as therapeutic options using mutagenesis-based remodeling and MD simulations.Semantic proximity Read ↗

The inhibitory effect of common food spices bioactive compounds against KRAS G12C and KRAS G12D: an in-silico approachSemantic proximity Read ↗

Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.